» Articles » PMID: 34696525

The Role of RASs /RVs in the Current Management of HCV

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2021 Oct 26
PMID 34696525
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The approval of combination therapies with direct-acting antiviral (DAA) regimens has led to significant progress in the field of hepatitis C virus (HCV) treatment. Although most patients treated with these agents achieve a virological cure, resistance to DAAs is a major issue. The rapid emergence of resistance-associated substitutions (RASs), in particular in the context of incomplete drug pressure, has an impact on sustained virological response (SVR) rates. Several RASs in NS3, NS5A and NS5B have been linked with reduced susceptibility to DAAs. RAS vary based on HCV characteristics and the different drug classes. DAA-resistant HCV variant haplotypes (RVs) are dominant in cases of virological failure. Viruses with resistance to NS3-4A protease inhibitors are only detected in the peripheral blood in a time frame ranging from weeks to months following completion of treatment, whereas NS5A inhibitor-resistant viruses may persist for years. Novel agents have been developed that demonstrate promising results in DAA-experienced patients. The recent approval of broad-spectrum drug combinations with a high genetic barrier to resistance and antiviral potency may overcome the problem of resistance.

Citing Articles

Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries.

Mustafa A, Davlidova S, Abidi S, Begimbetova D, Heimer R, Vermund S BMJ Open Gastroenterol. 2025; 12(1).

PMID: 39848793 PMC: 11758705. DOI: 10.1136/bmjgast-2024-001657.


Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks.

Fedorchenko S, Klimenko Z, Martynovich T, Solianyk I, Suprunenko T J Virol. 2025; 99(2):e0184324.

PMID: 39840947 PMC: 11852967. DOI: 10.1128/jvi.01843-24.


The prevalence of hepatitis C virus genotypes and factors associated with cirrhosis, fatty liver, and viral load: A registry-based cross-sectional cohort study in Western Iran during 1999-2023.

Sayad B, Bozorgomid A, Sayad N, Azhdari M, Bahadori M, Rezaeian S Health Sci Rep. 2024; 7(9):e70079.

PMID: 39314838 PMC: 11417008. DOI: 10.1002/hsr2.70079.


An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences.

Khalil R, Al-Mahzoum K, Barakat M, Sallam M Pathogens. 2024; 13(8).

PMID: 39204274 PMC: 11356961. DOI: 10.3390/pathogens13080674.


Contemporary Insights into Hepatitis C Virus: A Comprehensive Review.

Sallam M, Khalil R Microorganisms. 2024; 12(6).

PMID: 38930417 PMC: 11205832. DOI: 10.3390/microorganisms12061035.


References
1.
Sheldon J, Beach N, Moreno E, Gallego I, Pineiro D, Martinez-Salas E . Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus. J Virol. 2014; 88(20):12098-111. PMC: 4178724. DOI: 10.1128/JVI.01860-14. View

2.
de Ledinghen V, Laforest C, Hezode C, Pol S, Renault A, Alric L . Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study. Clin Infect Dis. 2017; 66(7):1013-1018. DOI: 10.1093/cid/cix916. View

3.
Wang G, Schnell G, Kort J, Sidhu G, Schuster L, Tripathi R . Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir. J Hepatol. 2021; 75(4):820-828. DOI: 10.1016/j.jhep.2021.04.057. View

4.
Di Maio V, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S . Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. Liver Int. 2021; 41(8):1802-1814. DOI: 10.1111/liv.14797. View

5.
Sarrazin C . The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2015; 64(2):486-504. DOI: 10.1016/j.jhep.2015.09.011. View